Thanks.. I would still very much like to reduce the total run time, in a way which is acceptable in cGMP.
1. Could I exclude or reduce the number of injections required for system suitability, for precision (6)? Under what circumstances is this allowed?
2. The samples don't degrade, they are frozen .. it's the concentration of the analytes in the samples, which could be between 1% to 90% of the calibration curve range, depending on the manufacturing process. So am I correct that I
don't have to put in several levels of the standard, as long as I prove during validation that the calibration curve is linear?
3. Which is preferable, a replicate injection, or a replicate preparation?
4. Since the FDA's requirements for 6 replicate injections originate from the same vial, should they have reduced/no weighting in generating a calibration curve?
Sorry for so many questions, but the regulatory requirements have always seemed somewhat arbitrary to me, so I'd very much appreciate everyone's opinions.
Also forgot : THe sequence should include the blank. So it could be up to 30 h now